Daewoong Pharmaceutical has launched an AI-driven drug development system called DAVID, consisting of an 800 million-compound database for discovering new drugs. The system includes AIVS for uncovering active substances and Daisy for predicting drug properties, leading to the discovery of weight loss, diabetes, and cancer treatments. By shortening the drug development process, Daewoong aims to compete with global pharma giants using AI. The use of AI in drug development has the potential to reduce costs and time significantly, making a substantial impact on human health. Daewoong plans to expand AI use throughout the drug development cycle, aligning with new trends in the pharmaceutical industry.
Source link
Daewoong Pharmaceutical digested 800 million compounds to facilitate AI drug discovery
